Back

Assessing survival and re-hospitalisation following transvenous lead extraction in cardiac resynchronisation therapy devices depending on reimplantation timing: a propensity score matched analysis.

25 April 2021 (16:15 - 17:10)
Organised by:
Congress Presentation Part of: Optimization of CRT Cardiac Resynchronisation Therapy (CRT) EHRA Premium Access EHRA 2021

About the speaker

Photo
Doctor Vishal Shahil Mehta

St Bartholomew's Hospital, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Impact of homeometric autoregulation using a stepwise change in heart rate on dP/dtmax and time to peak dP/dt with resynchronization therapy
Doctor H. Odland (Oslo, NO)
Abstract Video
Presentation thumbnail
Time delay to peak left ventricular pressure rise identifies the substrate for dyssynchronous heart failure and detects disease modification with resynchronization- an observational clinical study
Doctor H. Odland (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic pattern in V1, aVL and I as predictor of events in heart failure following cardiac resincronization
Mr J. Asensio Nogueira (Burgos, ES)
Abstract Slides Video
Presentation thumbnail
Duration of the preejection phase is less preload dependent and therefore a better marker of acute response to cardiac resynchronization therapy than maximum pressure rise
Mr M. Villegas-Martinez (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Long-term mortality benefit of CRT-D vs. CRT-P upgrade procedures from conventional devices without prior ventricular arrhythmias
Doctor W. Schwertner (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Optimization of CRT

The Event

Event poster

EHRA 2021

25 April 2021 16:15 CET
You may be interested in
thumbnail
Congress Session
Ventricular storm (2)
thumbnail
Congress Session
Navigating through heart failure device therapies
thumbnail
Congress Session
Conduction system pacing in challenging settings

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources